These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 16421019)

  • 1. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of infiltrating precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites.
    Ksander BR; Streilein JW
    J Immunol; 1990 Oct; 145(7):2057-63. PubMed ID: 1975822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
    Dace DS; Chen PW; Alizadeh H; Niederkorn JY
    J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local T helper cell signals by lymphocytes infiltrating intraocular tumors.
    Ksander BR; Acevedo J; Streilein JW
    J Immunol; 1992 Mar; 148(6):1955-63. PubMed ID: 1531848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful immunotherapy of an intraocular tumor in mice.
    Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
    Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses.
    Liu Y; Bi X; Xu S; Xiang J
    Cancer Res; 2005 Jun; 65(11):4955-62. PubMed ID: 15930318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3622-34. PubMed ID: 8258521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
    Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
    Hiroishi K; Tüting T; Tahara H; Lotze MT
    Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.